• genOway signed an exclusive U.S. distribution agreement with Taconic Biosciences to expand sales of its humanized preclinical models.
• Taconic will resell products purchased from genOway, making each Taconic sale incremental revenue for genOway.
• Deal terms aim to keep profitability close to direct sales, supporting near-term earnings leverage.
• Management flagged potential to double U.S. activity, its largest market with more than 50% of sales.
• Partnership adds nationwide U.S. commercial coverage through Taconic’s sales network, accelerating penetration of a market estimated above USD 1 billion annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. genOway SA published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.